阿比特龙单用或联合恩杂鲁胺治疗恩杂鲁胺进展的mCRPC
PLATO随机双盲安慰剂对照研究探讨恩杂鲁胺耐药后联合阿比特龙能否克服耐药。化疗初治mCRPC患者先接受开放标签恩杂鲁胺治疗,PSA进展后随机接受阿比特龙+泼尼松联合恩杂鲁胺或安慰剂。
要点
- 恩杂鲁胺治疗PSA进展后,联合阿比特龙未改善PFS。
- 联合组3级高血压和肝酶升高发生率高于对照组。
- 不推荐恩杂鲁胺进展后联合阿比特龙和泼尼松治疗。
核心结论
- 恩杂鲁胺单药治疗PSA进展后,联合阿比特龙和泼尼松不改善无进展生存,且毒性增加,不推荐使用。
研究设计与样本
- 随机、双盲、安慰剂对照研究(PLATO,NCT01995513)。
- 第一周期:化疗初治mCRPC患者接受开放标签恩杂鲁胺160 mg每日一次。
- 第13和21周无PSA升高的患者继续治疗至PSA进展,然后1:1随机进入第二周期。
- 第二周期:阿比特龙1000 mg每日一次+泼尼松5 mg每日两次,联合恩杂鲁胺或安慰剂。
- 主要终点为影像学或明确临床进展或研究期间死亡的无进展生存期。
主要发现
- 第一周期入组509例患者,第二周期251例随机分配。
- 次要终点(至PSA进展时间和PSA反应)无差异。
- 联合组3级高血压发生率10% vs 2%,ALT升高6% vs 2%,AST升高2% vs 0%。
关键数值与推荐
- PSA进展定义:较最低点升高≥25%且≥2 ng/mL。
- 联合组3级高血压10% vs 2%,ALT升高6% vs 2%,AST升高2% vs 0%。
临床怎么用
- 恩杂鲁胺治疗期间出现PSA进展的mCRPC患者,不应联合阿比特龙和泼尼松治疗。
- 联合方案增加高血压和肝酶升高风险,需密切监测。
局限性
- 第二周期样本量251例,可能不足以检测较小差异。
- 研究仅纳入化疗初治且恩杂鲁胺治疗无PSA升高的特定人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Enzalutamide resistance could result from raised androgens and be overcome by combination with abiraterone acetate. PLATO ( ClinicalTrials.gov identifier: NCT01995513) interrogated this hypothesis using a randomized, double-blind, placebo-controlled design. Patients and Methods In period one, men with chemotherapy-naïve metastatic castration-resistant prostate cancer received open-label enzalutamide 160 mg daily. Men with no prostate-specific antigen (PSA) increase at weeks 13 and 21 were treated until PSA progression (≥ 25% increase and ≥ 2 ng/mL above nadir), then randomly assigned at a one-to-one ratio in period two to abiraterone acetate 1,000 mg daily and prednisone 5 mg twice daily with either enzalutamide or placebo (combination or control group, respectively) until disease progression as defined by the primary end point: progression-free survival (radiographic or unequivocal clinical progression or death during study). Secondary end points included time to PSA progression and PSA response in period two. Results Of 509 patients enrolled in period one, 251 were randomly assigned in period two. Median progression-free survival was 5.7 months in the combination group and 5.6 months in the control group (hazard ratio, 0.83; 95% CI, 0.61 to 1.12; P = .22). There was no difference in the secondary end points. Grade 3 hypertension (10% v 2%) and increased ALT (6% v 2%) or AST (2% v 0%) were more frequent in the combination than the control group. Conclusion Combining enzalutamide with abiraterone acetate and prednisone is not indicated after PSA progression during treatment with enzalutamide alone; hypertension and elevated liver enzymes are more frequent with combination therapy.
引用
- Attard G, Borre M, Gurney H, et al. Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment. J Clin Oncol. 2018. PMID: 30028657. doi:10.1200/JCO.2018.77.9827
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。